Form 4: Mineralys CMO Executes Option, Sells Shares

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, executed stock options and subsequently sold 417 common shares as part of a pre-arranged 10b5-1 trading plan.

Summary

• David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, Inc. (MLYS), reported transactions on March 17, 2026.
• Rodman acquired 417 shares of common stock by exercising stock options at a price of $15.44 per share.
• Concurrently, Rodman disposed of 417 shares of common stock through a sale at a price of $25.65 per share.
• Both transactions were executed pursuant to a Rule 10b5-1 trading plan, which was adopted on October 6, 2025.
• Following these transactions, Rodman's direct beneficial ownership of common stock is 76,140 shares.
• The stock option exercised was part of a grant that vested 25% on the first anniversary of the grant date, with the remainder vesting in 36 substantially equal monthly installments thereafter, and has an expiration date of March 17, 2033.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While the officer profited from the transaction, it was a pre-scheduled event under a 10b5-1 plan and does not reflect a change in company fundamentals or a significant shift in insider sentiment.

Positives

• The Chief Medical Officer realized a profit from the option exercise and subsequent sale, indicating the company's stock price was above the option's exercise price.

Negatives

• The Chief Medical Officer reduced his direct beneficial ownership of common stock by 417 shares following the transactions.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under pre-arranged 10b5-1 plans, are common occurrences in publicly traded companies. These plans allow insiders to sell shares at predetermined times or prices to avoid accusations of trading on material non-public information. This specific transaction by Mineralys Therapeutics' CMO is a routine event for personal financial management and does not typically signal a change in the company's operational outlook or strategic direction.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction (option exercise and sale) executed under a pre-arranged 10b5-1 plan. Such transactions are typically for personal financial management and do not provide new material information about the company's operational performance or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Mineralys Therapeutics, MLYS, Form 4, Insider Trading, Stock Option Exercise, Stock Sale, 10b5-1 Plan, Chief Medical Officer, David Malcom Rodman